The Small Animal Imaging (In Vivo) Market Size was valued at USD 1.16 billion in 2023 and is expected to reach USD 2.27 billion by 2032 and grow at a CAGR of 7.76% over the forecast period 2024-2032. This report points towards the shifting imaging modality trends in regions due to advancing technology and growing research applications. Research funding and investment trends, as well as increasing healthcare and preclinical research expenditures in key markets, determine the application of advanced imaging solutions. Moreover, it also delves into market penetration and rising acceptance of small animal imaging technologies, driven by AI, automation, imaging accuracy, and efficiency-boosting innovations. The report further evaluates regulatory and compliance patterns impacting market development, influencing product approvals, and standardization in preclinical research.
Drivers
The small animal imaging (in vivo) market is driven by rising demand for preclinical research, advancements in imaging technologies, and increasing investments in drug discovery.
The increasing burden of chronic illnesses like cancer and neurological diseases has driven the pace of research on small animal models, increasing the demand for high-resolution imaging modalities such as PET, MRI, and optical imaging. Advances in technology, including AI-assisted imaging, hybrid imaging devices (PET/CT, PET/MRI), and high-field MRI, have greatly enhanced diagnostic precision and effectiveness. The biotechnology and pharmaceutical industries are heavily investing in preclinical trials, with global pharma R&D expenditure hitting USD 238 billion in 2022. The growing use of molecular imaging methods for drug efficacy testing and biomarker studies has also driven market growth. Government programs, including NIH funding for biomedical imaging research, also aid in market growth. In addition, the emergence of contract research organizations (CROs) that provide imaging services has increased the availability of advanced imaging for researchers. The confluence of 3D and 4D imaging, coupled with AI-powered image analysis, is transforming preclinical research and rendering small animal imaging more effective and informative. All these, in turn, are driving the small animal imaging market to expand rapidly, which makes it an integral part of preclinical drug development.
Restraints
The high cost of imaging systems and operational expenses remain significant restraints in the small animal imaging (in vivo) market.
Next-generation imaging devices like micro-MRI and PET/SPECT scanners have a price range of USD 200,000 to USD 2 million and are thus budget-inhibitable for small-scale research laboratories and educational institutions. The maintenance as well as the running expenses of these advanced pieces of equipment additionally load research units. The necessity of trained technical staff to utilize and interpret the imaging data further hinders use, as research adoption is stunted by inadequacies of skilled personnel. Regulatory restrictions also hinder small animal imaging research, since adherence to animal welfare regulations (e.g., AAALAC, IACUC guidelines) increases the complexity and duration of research studies. In addition, the limited availability of radiotracers for nuclear imaging modalities (PET/SPECT) restricts their widespread use. Data storage and processing capacity are also limiting factors since high imaging data sets need large amounts of computational resources. Researchers tend to have a hard time standardizing imaging protocols between laboratories, and thus it is challenging to compare studies. These operational and cost hurdles, combined with regulatory and logistical hurdles, hinder market penetration and the availability of sophisticated imaging technologies in preclinical research.
Opportunities
The expansion of AI-driven imaging solutions, increasing demand for personalized medicine, and rising investments in preclinical research offer substantial opportunities for the small animal imaging (in vivo) market.
The use of AI and machine learning algorithms in imaging analysis facilitates quicker and more precise image processing, lowering the possibility of human error and increasing efficiency. Increased interest in precision medicine has created a higher demand for imaging methods to give sophisticated molecular and functional information regarding disease development. Additionally, the creation of portable and affordable imaging technologies, like benchtop MRI scanners and miniaturized optical imaging tools, is bringing sophisticated imaging within the reach of smaller research institutions. Increased use of multimodal imaging, where PET, MRI, and optical imaging are combined for complete disease modeling, is another highly profitable opportunity area. The growth in CROs that provide imaging services also lowers the burden on individual research centers, thus facilitating wider implementation of advanced imaging modalities. Government support and funding for biomedical research and drug discovery also provide an impetus for market growth. New contrast agents and radiotracers further improve imaging capability, creating new research opportunities in oncology, neurology, and cardiovascular research.
Challenges
The small animal imaging (in vivo) market faces challenges related to data standardization, ethical concerns, and technological integration.
One of the main challenges is the absence of standardization in imaging protocols, resulting in variability in data interpretation among different research centers. This hinders the ability to compare study outcomes and verify findings, thereby slowing scientific progress. Ethical issues related to animal research are also a challenge, as tighter controls on animal testing have resulted in more scrutiny and restrictions on preclinical imaging studies. The technical and operational challenges presented by the complexity of multimodal imaging systems, including the need for sophisticated synchronization of MRI, PET, SPECT, and optical imaging, present technical and operational challenges. The processing times of long durations for high-resolution imaging data slow down research workflows. Researchers also encounter false positives and false negatives in imaging findings, affecting the validity of preclinical studies. The scarcity of certain radiotracers for small animal PET/SPECT imaging further adds to the challenge of research. Yet another issue is scalability in the form of AI-powered imaging software since most research institutes are not equipped to implement high-performance computing to support real-time analysis of images. It demands mutual coordination between technology suppliers, regulatory authorities, and researchers in improving the reliability and efficiency of imaging.
By Modality
Optical imaging systems dominated the market in 2023 with a share of 36.6% due to their relative sensitivity, affordability, and real-time imaging. They are used extensively for bioluminescence and fluorescence imaging to facilitate non-invasive tracking of disease status, gene expression, and drug activity. Preclinical oncology studies and molecular imaging research have increasingly contributed to reinforcing their market leadership.
The micro-MRI segment is anticipated to be the most rapidly growing modality as it offers higher soft tissue contrast and high-resolution anatomical detail capability. Increasing requirements of longitudinal research and studies of neurological diseases have fueled the uptake of micro-MRI. Further, improvements in high-field MRI systems and contrast agents are increasing their usage, mainly in brain imaging and functional evaluation.
By Application
The segment of biodistribution studies led the market with a share of 31.8% in 2023, mainly due to its pivotal position in drug development and pharmacokinetic studies. Researchers widely utilize imaging methods to follow the distribution of therapeutic drugs, nanoparticles, and gene therapies in small animals. The growing requirement for accurate formulation assessments of drugs and regulatory demand for preclinical drug trials have also driven it to be the market leader.
The segment of cancer cell detection is anticipated to see the most growth with the increased incidence of cancer and the heightened need for tumor imaging at an early stage. Small animal imaging modalities, especially optical imaging and PET/SPECT, find extensive application in tumor localization, tracking response to treatment, and evaluating metastasis. The expansion in oncology drug development investment and personalized medicine strategies is expected to propel explosive growth in this segment.
North America was the leading market for small animal imaging (in vivo) in 2023, with a market share of 36.1%, facilitated by its established biotechnology and pharmaceutical research base, sophisticated healthcare infrastructure, and heavy investment in preclinical research. The presence of world-class research institutions, contract research organizations (CROs), and premier imaging technology providers further enhanced the position of the region. The voluminous use of advanced imaging modalities, including optical imaging, micro-MRI, and nuclear imaging, is driven by mounting funding for drug discovery, cancer research, and studies of neurological disorders. Moreover, government efforts, including NIH funding for biomedical imaging, continue to drive market growth.
The Asia-Pacific region is expected to be the fastest-growing market due to increasing investments in preclinical research, the increasing number of CROs, and rising demand for advanced imaging technologies in drug discovery. China, Japan, and India are experiencing high growth in life sciences research, backed by government support and private-sector partnerships. In addition, the reduced cost of preclinical trials and an increasing focus on precision medicine and personalized treatments are drawing international pharmaceutical firms to open up research activities in the region. This explosive growth makes Asia-Pacific a central driver for the future growth of the small animal imaging market.
Aspect Imaging Ltd. – M-Series, GeoMRI
PerkinElmer, Inc. – IVIS Spectrum Series, Quantum GX2 MicroCT Imaging System
FUJIFILM Holdings Corporation – VisualSonics Vevo 3100, VisualSonics Vevo LAZR-X
Miltenyi Biotec – MACSQuant Analyzer Series, UltraMicroscope II
Thermo Fisher Scientific Inc. – Amira-Avizo Software, CellInsight CX7 LZR
Bruker – BioSpec MRI Series, Albira Si
Siemens AG – Inveon, SimPET
Promega Corporation – NanoLuc, GloMax
Mediso – nanoScan PET/MRI, nanoScan SPECT/CT
TriFoil Imaging – InSyTe FLECT/CT, InSyTe PET/CT
Recent Developments
In Dec 2024, Siemens Healthineers completed the acquisition of Advanced Accelerator Applications Molecular Imaging, expanding its PETNET Solutions network. This acquisition adds 13 manufacturing sites across Europe and enhances radiopharmaceutical distribution in Switzerland, complementing its existing 47 radiopharmacies in the U.S.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 1.16 billion |
| Market Size by 2032 | USD 2.27 billion |
| CAGR | CAGR of 7.76% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Modality [Optical Imaging Systems (Bioluminescence Imaging, Cerenkov Luminescence Imaging, Fluorescence Imaging), Micro-magnetic Resonance Imaging, Nuclear Imaging (Micro Positron Emission Tomography (Micro PET), Micro Single Photon Emission Computerized Tomography (Micro SPECT)), Other Imaging Modalities (Micro Computerized Tomography Imaging, Micro Ultrasound Imaging)] • By Application [Monitoring Drug Treatment Response, Biodistribution Studies, Cancer Cell Detection, Biomarkers, Longitudinal Studies, Epigenetics] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Aspect Imaging Ltd., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Miltenyi Biotec, Thermo Fisher Scientific Inc., Bruker, Siemens AG, Promega Corporation, Mediso, TriFoil Imaging. |
Ans: The Small Animal Imaging (In Vivo) market is anticipated to grow at a CAGR of 7.76% from 2024 to 2032.
Ans: The market is expected to reach USD 2.27 billion by 2032, increasing from USD 1.16 billion in 2023.
Ans: The small animal imaging (in vivo) market is driven by rising demand for preclinical research, advancements in imaging technologies, and increasing investments in drug discovery.
Ans: The high cost of imaging systems and operational expenses remain significant restraints in the small animal imaging (in vivo) market.
Ans: North America dominated the Small Animal Imaging (In Vivo) market.
Table of content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Imaging Modality Trends (2023), by Region
5.2 Research Funding & Investments Trends (2023-2032)
5.3 Healthcare & Preclinical Research Spending (2023), by Region
5.4 Market Penetration & Adoption Rate of Small Animal Imaging Technologies
5.5 Regulatory & Compliance Trends Affecting Market Growth
5.6 AI, Automation & Technological Advancements in Small Animal Imaging
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Service Benchmarking
6.3.1 Service specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Service launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Small Animal Imaging (In Vivo) Market Segmentation, by Modality
7.2 Optical Imaging Systems
7.2.1 Optical Imaging Systems Market Trends Analysis (2020-2032)
7.2.2 Optical Imaging Systems Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Bioluminescence Imaging
7.2.3.1 Bioluminescence Imaging Market Trends Analysis (2020-2032)
7.2.3.2 Bioluminescence Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Cerenkov Luminescence Imaging
7.2.4.1 Cerenkov Luminescence Imaging Market Trends Analysis (2020-2032)
7.2.4.2 Cerenkov Luminescence Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Fluorescence Imaging
7.2.5.1 Fluorescence Imaging Market Trends Analysis (2020-2032)
7.2.5.2 Fluorescence Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Micro-magnetic Resonance Imaging
7.3.1 Micro-magnetic Resonance Imaging Market Trends Analysis (2020-2032)
7.3.2 Micro-magnetic Resonance Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Nuclear Imaging
7.4.1 Nuclear Imaging Market Trends Analysis (2020-2032)
7.4.2 Nuclear Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.3 Micro Positron Emission Tomography (Micro PET)
7.4.3.1 Micro Positron Emission Tomography (Micro PET) Market Trends Analysis (2020-2032)
7.4.3.2 Micro Positron Emission Tomography (Micro PET) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.4 Micro Single Photon Emission Computerized Tomography (Micro SPECT)
7.4.4.1 Micro Single Photon Emission Computerized Tomography (Micro SPECT) Market Trends Analysis (2020-2032)
7.4.4.2 Micro Single Photon Emission Computerized Tomography (Micro SPECT) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Other Imaging Modalities
7.5.1 Other Imaging Modalities Market Trends Analysis (2020-2032)
7.5.2 Other Imaging Modalities Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5.3 Micro Computerized Tomography Imaging
7.5.3.1 Micro Computerized Tomography Imaging Market Trends Analysis (2020-2032)
7.5.3.2 Micro Computerized Tomography Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5.4 Micro Ultrasound Imaging
7.5.4.1 Micro Ultrasound Imaging Market Trends Analysis (2020-2032)
7.5.4.2 Micro Ultrasound Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Small Animal Imaging (In Vivo) Market Segmentation, by Application
8.2 Monitoring Drug Treatment Response
8.2.1 Monitoring Drug Treatment Response Market Trends Analysis (2020-2032)
8.2.2 Monitoring Drug Treatment Response Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Biodistribution Studies
8.3.1 Biodistribution Studies Market Trends Analysis (2020-2032)
8.3.2 Biodistribution Studies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Cancer Cell Detection
8.4.1 Cancer Cell Detection Market Trends Analysis (2020-2032)
8.4.2 Cancer Cell Detection Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Biomarkers
8.5.1 Biomarkers Market Trends Analysis (2020-2032)
8.5.2 Biomarkers Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Longitudinal Studies
8.6.1 Longitudinal Studies Market Trends Analysis (2020-2032)
8.6.2 Longitudinal Studies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.7 Epigenetics
8.7.1 Epigenetics Market Trends Analysis (2020-2032)
8.7.2 Epigenetics Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.2.4 North America Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.2.5.2 USA Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.2.6.2 Canada Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.2.7.2 Mexico Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.1.5.2 Poland Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.1.6.2 Romania Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.4 Western Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.5.2 Germany Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.6.2 France Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.7.2 UK Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.8.2 Italy Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.9.2 Spain Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.12.2 Austria Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.4.4 Asia Pacific Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.4.5.2 China Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.4.5.2 India Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.4.5.2 Japan Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.4.6.2 South Korea Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.2.7.2 Vietnam Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.4.8.2 Singapore Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.4.9.2 Australia Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.5.1.4 Middle East Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.5.1.5.2 UAE Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.5.2.4 Africa Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.6.4 Latin America Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.6.5.2 Brazil Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.6.6.2 Argentina Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.6.7.2 Colombia Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Modality (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Small Animal Imaging (In Vivo) Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10. Company Profiles
10.1 Aspect Imaging Ltd.
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
10.1.4 SWOT Analysis
10.2 PerkinElmer, Inc.
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 FUJIFILM Holdings Corporation
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Miltenyi Biotec
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Thermo Fisher Scientific Inc.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Bruker
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Siemens AG
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Promega Corporation
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Mediso
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 TriFoil Imaging
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Products/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Modality
Optical Imaging Systems
Bioluminescence Imaging
Cerenkov Luminescence Imaging
Fluorescence Imaging
Micro-magnetic Resonance Imaging
Nuclear Imaging
Micro Positron Emission Tomography (Micro PET)
Micro Single Photon Emission Computerized Tomography (Micro SPECT)
Other Imaging Modalities
Micro Computerized Tomography Imaging
Micro Ultrasound Imaging
By Application
Monitoring Drug Treatment Response
Biodistribution Studies
Cancer Cell Detection
Biomarkers
Longitudinal Studies
Epigenetics
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Microneedle Drug Delivery Systems Market Size was USD 6.1 billion in 2023, expected to reach USD 11.6 billion by 2032, growing at a CAGR of 7.4%.
The Cognitive Behavioral Therapy Market Size was valued at USD 6.69 Billion in 2023, and is expected to reach USD 25.27 Billion by 2032, and grow at a CAGR of 16.81%.
Airway Disease Treatment Market was valued at $ 2.23 billion in 2023 and is expected to reach $ 3.54 billion by 2032, growing at a CAGR of 5.29% from 2024-2032.
Fecal Calprotectin Testing Market was valued at USD 4.51 billion in 2023 and is expected to reach USD 12.23 billion by 2032, growing at a CAGR of 11.61% from 2024-2032.
The Host Cell Protein Testing Market Size was valued at USD 2.15 Bn in 2023 and will reach USD 4.34 Bn by 2032 and grow at a CAGR of 8.14% by 2024-2031.
The Asthma Treatment Market Size was valued at USD 26.7 billion in 2023, and is expected to reach USD 42.13 billion by 2032, and grow at a CAGR of 5.2% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
